A

Adaptimmune Therapeutics plc
D

ADAP

0.66000
USD
0.03
(4.46%)
Market Closed
Volume
9,945
EPS
-0
Div Yield
-
P/E
-4
Market Cap
168,882,917
OverviewSignalsIdeasNews
Related Instruments
    EOSUSD
    EOSUSD
    0.06588
    (10.96%)
    0.7412875 USD
    E
    EOS
    -0.220
    (-0.96%)
    22.720 USD
    L
    LINK
    0.08000
    (1.61%)
    5.06000 USD
    T
    TRX
    -0.00600
    (-1.62%)
    0.36500 USD
    More
News

Title: Adaptimmune Therapeutics plc

Sector: Healthcare
Industry: Biotechnology
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.